| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6982096 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(5 years ago) | |
| US8273379 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(5 years ago) | |
| US6855339 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(5 years ago) | |
| US6884439 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(5 years ago) | |
| US6723351 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(5 years ago) | |
| US6861076 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(5 years ago) | |
Trisenox is owned by Cephalon.
Trisenox contains Arsenic Trioxide.
Trisenox has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Trisenox are:
- US6982096
- US8273379
- US6855339
- US6884439
- US6723351
- US6861076
Trisenox was authorised for market use on 13 October, 2017.
Trisenox is available in injectable;injection dosage forms.
Trisenox can be used as treatment of acute promyelocytic leukemia (apl) in patients whose apl is characterized by the presence of the (15;17) translocation or pml/rar-alpha gene expression, treating patients with acute promyelocytic leukemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterized by the presence of the t(15;17) translocation or pml/rar-alpha gene expression, in combination with tretinoin, treating adults and pediatric patients 1 year and older with newly-diagnosed low-risk acute promyelocytic leukemia (apl) characterized by the presence of the t(15;17) translocation or pml/rar-a gene expression.
The generics of Trisenox are possible to be released after 12 January, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-167) | Jan 12, 2025 |
Drugs and Companies using ARSENIC TRIOXIDE ingredient
Market Authorisation Date: 13 October, 2017
Treatment: In combination with tretinoin, treating adults and pediatric patients 1 year and older with newly-diagnosed low-risk acute promyelocytic leukemia (apl) characterized by the presence of the t(15; 17) t...
Dosage: INJECTABLE;INJECTION
TRISENOX family patents
